CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
FoTvdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04667247
NCT04667247Phase 2Completed
CompareCT.gov

Multicenter Double Blind, Placebo Controlled RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19

Gordon Saxe·interventional·Posted Dec 14, 2020·Updated Aug 19, 2025

In Brief

A Phase 2 clinical trial evaluating FoTv for COVID-19. Completed, enrolled 54 participants across 2 sites.

Detailed Summary

This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. The study aims to establish the safety and feasibility of the use of FoTv vs placebo in 66 total subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsUniversity of California, Los Angeles, University of California, Irvine

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedDec 14, 2020
Enrollment StartDec 23, 2020
Primary CompletionMar 21, 2022
Study CompletionMay 4, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.5 years ago

Interventions

FoTvdrug

8 capsules three times a day for 14 consecutive days.